Device, method, and program for calculating risk index of mild cognitive disorder

A non-invasive method using intestinal microbiota data from stool samples and questionnaires calculates MCI risk, offering personalized dietary solutions for cognitive improvement.

JP2024172562AActive Publication Date: 2024-12-12SYMBIOSIS SOLUTIONS INC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023090352
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-12
Estimated Expiration
2043-05-31

AI Technical Summary

Technical Problem

Existing methods for evaluating the risk of mild cognitive impairment (MCI) require invasive blood sampling to measure L-ergothioneine concentrations, lacking a non-invasive method to calculate MCI risk using stool specimens and questionnaires.

Method used

A system and method to extract data on intestinal microorganisms associated with MCI from stool samples and questionnaire responses, using a model to calculate a risk index based on these factors, including a risk index calculation device and program.

Benefits of technology

Enables non-invasive calculation of MCI risk using stool specimens and questionnaires, providing accurate risk assessment and personalized recommendations for improving cognitive function through targeted dietary interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024172562000001_ABST
    Figure 2024172562000001_ABST
Patent Text Reader

Abstract

To provide a technique of calculating the risk of a mild cognitive disorder for a subject who handed in a stool sample and an inquiry.SOLUTION: The device for calculating the risk of a mild cognitive disorder includes: an extraction unit for extracting second data on a factor or an enteric microorganism which suggests a connection with a mild cognitive disorder from first data on gut flora of a subject; and a calculation unit for inputting the second data into a model which calculates the possibility that the subject is having a mild cognitive disorder by using, as a variable, third data on one or plural enteric microorganisms showing the difference between the gut flora of a healthy person and the gut flora of a person who is having the mild cognitive disorder, and calculating the risk of the mild cognitive disorder of the subject.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] An embodiment of the present invention relates to a technology for calculating a disease evaluation index using gut microbiota data, and in particular provides a technology for calculating the risk of mild cognitive impairment for a subject who has submitted a stool sample and a questionnaire. [Background technology]

[0002] Research is being conducted on food compositions for maintaining brain health, particularly cognitive function. Patent Document 1 discloses that L-ergothioneine is a food composition useful for improving cognitive function in humans.

[0003] In addition, a technology has been developed to calculate a disease evaluation index using the human intestinal flora. Patent Document 2 discloses a technology that uses a structural equation model to estimate the risk of a user who submits a stool sample contracting a disease such as atopic dermatitis. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2019-180364 A [Patent Document 2] Patent No. 7270143 Summary of the Invention [Problem to be solved by the invention]

[0005] However, paragraph 0056 of Patent Document 1 merely indicates that there is a correlation between the blood concentration of L-ergothioneine and memory. Therefore, when investigating the memory of a subject, it is necessary to collect the subject's blood and measure the blood concentration of L-ergothioneine.

[0006] The present invention was completed through intensive research focusing on such problems, and its purpose is to provide a technology for calculating the risk of mild cognitive impairment for subjects who submit a stool sample and questionnaire. [Means for solving the problem]

[0007] In order to solve the above problems, the present invention provides a risk index calculation device for mild cognitive impairment, which includes an extraction unit that extracts second data on intestinal microorganisms or factors suggesting an association with mild cognitive impairment from first data on the intestinal microbiota of a subject, and a calculation unit that inputs the second data into a model that calculates the probability that the subject has mild cognitive impairment using third data on one or more intestinal microorganisms that show a difference between the intestinal microbiota of a healthy person and the intestinal microbiota of a person suffering from mild cognitive impairment as a variable, and calculates the subject's risk of mild cognitive impairment.

[0008] Another invention is a method for calculating a risk index of mild cognitive impairment, in which a computer inputs first data regarding the subject's intestinal microbiota into a model that calculates the probability that the subject has mild cognitive impairment, using as variables third data regarding one or more intestinal microorganisms that show a difference between the intestinal microbiota of a healthy person and the intestinal microbiota of a person suffering from mild cognitive impairment, and calculates the subject's risk of mild cognitive impairment.

[0009] Another invention is a program for calculating a risk index for mild cognitive impairment that causes a computer to execute the following steps: an extraction step of extracting second data on intestinal microorganisms or factors suggested to be associated with mild cognitive impairment from first data on the intestinal microbiota of a subject; and a calculation step of inputting the second data into a model that calculates the probability that the subject has mild cognitive impairment, using third data on one or more intestinal microorganisms that show a difference between the intestinal microbiota of a healthy person and the intestinal microbiota of a person suffering from mild cognitive impairment as a variable, and calculating the subject's risk of mild cognitive impairment. Effect of the Invention

[0010] According to the present invention, it is possible to provide a technique for calculating the risk of a disease that a subject wishes to be evaluated for, the subject having submitted a stool sample and a questionnaire. [Brief description of the drawings]

[0011] [Figure 1] 1 is an overall schematic diagram of a disease evaluation index calculation system according to an embodiment of the present invention. [Diagram 2] 13 is a flowchart of a disease evaluation index calculation process according to the present embodiment. [Diagram 3] 1 is a table showing questionnaire items for investigating basic information of subjects and examinees according to the present embodiment. [Figure 4] 1 is a table showing conditions of a control group according to the present embodiment. [Diagram 5] 1 is a table showing conditions for an MCI group according to the present embodiment. [Figure 6] FIG. 13 is a diagram for explaining the selection of gut microbial variables when the population is female according to this embodiment. [Figure 7] FIG. 7 is a table showing the effect size, application to the association model, and factors associated with MCI for each of the gut bacteria in FIG. 6. [Figure 8] FIG. 13 is a diagram for explaining the selection of gut microbial variables when the population is male according to this embodiment. [Figure 9]9 is a table showing the effect size value, application to the association model, and factors associated with MCI for each of the gut bacteria in FIG. 8. [Figure 10] FIG. 1 is a hypothesis conceptual diagram regarding the influence of intestinal bacteria related to MCI according to the present embodiment. [Figure 11] FIG. 11 is an enlarged view of a portion of FIG. [Figure 12] FIG. 1 is a diagram showing the relationship between age and the occupancy rate of intestinal bacteria (the population is female) according to the present embodiment. [Figure 13] FIG. 13 is a diagram for explaining points added according to MCI-related factors according to the present embodiment. [Figure 14] FIG. 13 is a diagram showing the results of estimating parameters of the association model according to the present embodiment (the population is female). [Figure 15] FIG. 13 is a diagram for explaining a score estimation model after adding points and a risk calculation model according to this embodiment (the population is female). [Figure 16] FIG. 13 is a diagram showing the results of estimating parameters of an association model according to a modified example (with a male population). [Figure 17] FIG. 13 is a diagram for explaining a score estimation model after adding points and a risk calculation model according to a modified example (the population is male). [Figure 18] FIG. 13 is a diagram showing the results of ROC analysis of the risk value of MCI according to this embodiment (the population is female). [Figure 19] FIG. 13 is a diagram showing the results of ROC analysis on the risk value of MCI for the modified example (population is male). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The present invention will be described with reference to the drawings. In the drawings, the same reference numerals are used to designate the same parts, and the description will be omitted.

[0013] (Disease evaluation index calculation system) 1 is an overall schematic diagram of a disease evaluation index calculation system according to an embodiment of the present invention. The disease evaluation index calculation system includes a phase of creating a gut microbiota database (DB) from stool samples submitted by a large number of subjects, a phase of creating a model for one or more diseases (specific diseases), and a phase of calculating an evaluation index for the risk of a specific disease. Here, the large number of subjects are participants who provide samples (stool samples and questionnaire response data) used to create the model.

[0014] Below, we will explain mild cognitive impairment (hereinafter abbreviated as MCI), which is related to a decline in cognitive function, as an example of a specific disease. The risk of MCI indicates the probability of having or suffering from MCI. In addition, the gut microbiome is a collection of gut microorganisms that include intestinal bacteria (bacteria, archaea, etc.) that live in the intestine, as well as mold and yeast.

[0015] (Gut microbiome DB creation phase) In the gut microbiota DB creation phase, more than 10,000 subjects excrete feces in the toilet and collect fecal samples using a stool collection kit. Next, a DNA extraction company that receives the fecal samples inputs them into the gut microbial DNA extraction device 100, which outputs a DNA solution related to the gut microbiota.

[0016] The analysis company that receives the DNA solution inputs the DNA solution into the intestinal microbiota analyzer 200 and analyzes the intestinal microbiota. The analysis company stores the analysis result data in the intestinal microbiota DB 300. In this analysis, first, an ASV (Amplicon Sequence Variant) sequence unique to the intestinal microbiota of each subject is created. Next, a taxonomic group name is assigned to the intestinal microbiota data of each subject using a publicly available external DNA sequence database (e.g., the Ribosomal Database Project database). The taxonomic group name in this embodiment includes taxonomic group names of taxonomic classes such as family, genus, and species, and taxonomic group names used in publicly available external DNA sequence databases.

[0017] The gut microbiome DB 300 associates ID (identification number) information of each subject with the gut microbiome data of that subject. Although the DNA extraction company and the analysis company are described separately, the same company may perform both the extraction work and the analysis work.

[0018] Next, the subjects who have submitted the stool samples answer a questionnaire using their ID information and submit the questionnaire to a questionnaire collection company. The questionnaire collection company stores the completed questionnaire response data in the questionnaire DB 400.

[0019] The questionnaire survey surveys detailed information including the subject's attribute information, body mass index (BMI), bowel frequency, lifestyle habits (drinking, smoking, exercise frequency), disease status, sleep status, CES-D score, presence or absence of Helicobacter pylori treatment, hospitalization or surgery experience, and prescription or over-the-counter drug use status. In this embodiment, the subject's attribute information refers to basic information such as gender, age, and childhood living area, and details will be described later.

[0020] For female subjects only, menstrual status and whether or not they are pregnant or breastfeeding will be surveyed. Disease status will be surveyed for 13 categories (MCI, atopic dermatitis, bone and / or joint disease, bronchial asthma, diabetes, dyslipidemia, gastrointestinal disease, heart disease, hypertension, kidney disease, liver disease, lower back and / or joint pain, and other diseases), and the name of the disease and whether or not they are currently receiving treatment will be surveyed. In other words, people with a disease include those who are currently suffering from it and / or those who have suffered from it in the past. Regarding the use of prescription and over-the-counter medications, we investigated whether the subjects were taking medications from 16 categories (medicines for gastric / duodenal ulcer / reflux esophagitis, hypertension medication, hyperlipidemia medication, diabetes medication, hypnotics, analgesics / antipyretics, allergy medication, angina medication, laxatives / constipation medication, osteoporosis medication, rheumatism medication, corticosteroids, antibiotics, cold medicine, antithrombotic drugs, and others) at the time of stool collection.

[0021] (Model creation phase) In the model creation phase, the model creator first selects a disease to be evaluated. The association model creation device 500 includes an input unit that accepts input of MCI as the selected disease, an extraction unit that extracts ID information of subjects related to MCI for each attribute of male and female from the questionnaire DB 400 and also extracts gut microbiota data of the corresponding ID information from the gut microbiota DB 300, and a creation unit that creates an association model by a creation method described below. The association model creation device 500 stores the created association model in the association model DB 600.

[0022] Next, the score estimation model creation device 700 extracts an association model from the association model DB 600, and creates a score estimation model by a creation method described later. The created score estimation model is stored in the score estimation model DB 800.

[0023] (Disease evaluation index calculation phase) In the disease evaluation index calculation phase, the evaluation company submits a stool sample collected with a stool collection kit and requests a person (hereinafter referred to as the subject) who wishes to be evaluated for risk of MCI to submit a stool sample as described in the gut microbiome DB creation phase. The subject's stool sample is processed by the gut microbial DNA extraction device 100 and the gut microbiome analysis device 200, similar to the stool samples of the multiple subjects described above. The subject's gut microbiome data is stored in the gut microbiome DB 300.

[0024] Furthermore, the MCI and the subject's ID information (including the subject's attribute information) are input to the disease evaluation index calculation device 900. Here, the subject's attribute information is also input to the disease evaluation index calculation device 900 from the questionnaire response data submitted by the subject. The questionnaire response data submitted by the subject may be input to the questionnaire DB 400, similar to the questionnaire response data of the multiple subjects described above. In this case, the disease evaluation index calculation device 900 only needs to extract the subject's questionnaire response data from the questionnaire DB 400. In this way, the subject is a person (user) who provides a sample (a stool sample and questionnaire response data) to have his / her risk of MCI evaluated.

[0025] The disease evaluation index calculation device 900 includes an input unit that receives input information, an extraction unit that extracts information related to the input information, a point adding unit that adds points to a score estimation model, a calculation unit that calculates an evaluation index using the added score estimation model, and an output unit that outputs an evaluation report. 910 in Fig. 1 indicates the above-mentioned point adding unit.

[0026] The input unit receives input of MCI as a specific disease and ID information of the subject. The extraction unit extracts information related to the ID information of the subject (attribute information of the subject and gut microbiota data) from the external gut microbiota DB300, and extracts a score estimation model related to MCI from the score estimation model DB800.

[0027] The score adding unit 910 adds points to the score estimation model using the subject's attribute information. The calculation unit inputs the subject's gut microbiota data into the added score estimation model and calculates an evaluation index for MCI risk. The output unit outputs an evaluation report based on the calculated evaluation index. Although the above description is given with separate businesses performing each phase, the same business may perform all phases.

[0028] (Flowchart of disease evaluation index calculation process) 2 is a flowchart of the disease evaluation index calculation process according to this embodiment. This process is divided into two processing groups: a first processing group (S100 to S120) that creates a score estimation model for each disease in advance, and a second processing group (S200 to S240) that calculates an evaluation index of the risk of MCI, which is the disease that the subject wishes to be evaluated for.

[0029] The first processing group includes a step of extracting gut microbiota data of multiple subjects for each disease (S100), a step of creating an association model for each disease (S110), and a step of creating a score estimation model for each disease (S120). The second processing group includes a step of inputting MCI as a disease that the subject wishes to evaluate (S200), a step of extracting gut microbiota data of the subject (S210), a step of adding points to the score estimation model using attribute information of the subject and / or information on gut bacteria corresponding to factors related to MCI (S220), a step of estimating the score of the latent variable using the score estimation model after adding points (S230), and a step of calculating an evaluation index for MCI risk (S240).

[0030] (Explanation of S100) In this embodiment, "MCI" is used as an example of a disease. S100 extracts gut microbiome data of a group of healthy people and a group of people suffering from MCI (people belonging to these groups correspond to the subjects mentioned above) from the gut microbiome DB300. Figure 3 is a table showing questionnaire items for investigating basic information of the subjects and examinees. Figures 4 and 5 show the conditions for extracting each group. These conditions include conditions that apply only to women. Please note that the questionnaire items in Figure 3 are investigated not only for the subjects but also for the examinees.

[0031] FIG. 3 is a table showing questionnaire items for investigating basic information of subjects and examinees according to this embodiment. This embodiment is a technology for calculating disease evaluation indexes for MCI using gut microbiota data of subjects. The gut microbiota of subjects and examinees may be influenced by their age, biological sex (hereinafter simply referred to as sex), and life background such as the area in which they lived during childhood. The questionnaire item numbers related to life background correspond to the 8th and 9th. In addition, the 10th item, the method of delivery, is asked as a factor in inheriting the mother's gut microbiota. For this reason, information that may be related to the gut microbiota data of subjects and examinees is called the basic information of subjects and examinees.

[0032] In this embodiment, attribute information of the subjects and examinees is investigated using the questionnaire items shown in Fig. 3. In order to investigate the effects of the subjects' gut microbiota and their living background, for example, the prefecture in which they mainly lived until the age of 3 is asked.

[0033] In this embodiment, since it is assumed that all the subjects and examinees are Japanese, the subjects' and examinees' countries of birth are not asked. However, the country of birth may be asked as a questionnaire item. The basic information of the subjects and examinees extracted from the questionnaire response data in this way will be referred to below as the subjects' and examinees' "attribute information." The attribute information includes the subjects' and examinees' backgrounds at the time of birth and the backgrounds of their lives during childhood.

[0034] FIG. 4 is a table showing the conditions of the control group according to this embodiment. The control group (Normal Control, hereinafter abbreviated as NC) is a group of healthy people who meet all of the conditions listed in FIG. 4. FIG. 5 is a table showing the conditions of the MCI group according to this embodiment. The group of people suffering from MCI (hereinafter abbreviated as MCI group) is a group of people who meet all of the conditions listed in FIG. 5. In this embodiment, each group is further divided by gender. The MCI group consists of 26 men in their 40s to 80s and 33 women in their 40s to 80s.

[0035] (Explanation of S110) S110 is a step of creating an association model for MCI. In this embodiment, an association model for MCI is created for each gender. In this embodiment, the male population uses gut microbiota data of 11 MCI subjects in their 70s and 17 control subjects without disease, and the female population uses gut microbiota data of 18 MCI subjects in their 70s and 23 control subjects without disease. Here, the reason why the MCI group is limited to the 70s is that this is the most common age group among subjects in their 40s to 80s. Note that the human gut microbiota may behave differently in the body of men and women, even if it is the same gut microbe.

[0036] First, the gut microbiome data extracted by the S100 is converted into a centered log-ratio (CLR) value to convert the count value of the gut microbiome data into a CLR value. This conversion process makes statistical processing easier.

[0037] Next, in this embodiment, a step (S115) of estimating gut microbe variables is performed. The gut microbe variables are gut microbes that are suggested to be associated with MCI. S115 is performed to search for one or more gut microbes that represent the difference in gut microbiota between the control group (NC) and the MCI group. In this embodiment, gut bacteria are selected for each male and female population using the effect amount between the NC and MCI groups as an index. Intestinal bacteria with an effect amount of more than 0.2 are classified and defined as gut bacteria that are abundant in the MCI group compared to the control group, and gut bacteria with an effect amount of less than -0.2 are classified and defined as gut bacteria that are abundant in the MCI group and gut bacteria that are abundant in the MCI group are different between males and females because the population is divided into males and females (see Figures 6 and 9 described later). In Figure 6 and subsequent figures, gut bacteria are given as an example of gut microbes.

[0038] FIG. 6 is a diagram for explaining the selection of gut microbe variables when the population according to this embodiment is female. The horizontal axis is the effect size, and the vertical axis is the name of gut bacteria (genus level). For convenience in creating a bar graph, gut bacteria with a positive effect size are represented as MCI, and gut bacteria with a negative effect size are represented as Healthy. In this way, gut bacteria with a positive effect size are more abundant in the gut microbiota of the MCI group, while gut bacteria with a negative effect size are less abundant in the gut microbiota of the MCI group. Therefore, by the process of S110, multiple gut bacteria that are estimated to contribute to the difference in gut microbiota between the control group and the MCI group can be estimated. Note that although there are actually 51 types of gut bacteria, only 26 types are displayed in FIG. 6 for the convenience of making the bar graph easier to see.

[0039] FIG. 7 is a table showing the effect size values, application to the association model, and factors related to MCI for the 51 types of intestinal bacteria mentioned above. Check marks indicate which intestinal bacteria are applied to the association model and which MCI-related factors they correspond to. MCI-related factors refer to factors or intestinal bacteria (intestinal microorganisms) that are suggested to be related to MCI. In addition, the intestinal bacteria with check marks in the "association model" column will be described later in FIG. 14.

[0040] In FIG. 7, ten MCI-related factors are listed. Specifically, they are: 1) mucin degradation, 2) IgA protease production, 3) promotion of serotonin secretion from enterochromaffin cells (EC cells), 4) oxidation of bile acids, 5) promotion of recovery of intestinal barrier function, 6) hydrogen production, 7) production of HDAC inhibitors, 8) protection of IgA from trypsin degradation, 9) intestinal bacteria abundant in MCI (in men), and 10) intestinal bacteria abundant in MCI (in women). In this embodiment, the MCI-related factors are classified into ten. However, the MCI-related factors are not limited to these, and may be one or more. They may also be other MCI-related factors.

[0041] There are some intestinal bacteria with values ​​in the "Healthy" column of the effect size that do not have a check mark in any of the MCI-related factors. These correspond to other MCI-related factors. For example, Prevotella corresponds to "intestinal bacteria with low MCI (for both men and women)" (see Figure 11 below). In addition, Flavonifractor, which is an intestinal bacteria with values ​​in the "MCI" column of the effect size that does not have a check mark in any of the MCI-related factors, corresponds to intestinal bacteria with high MCI (for both men and women) (see Figure 11 below). In addition, in the case of Figure 7, since the population is female, there is no check mark in the item "intestinal bacteria with high MCI (for men)". Also, please note that the names of intestinal bacteria are normally written in italics, but due to the character code that can be used in the specification, they are written in normal typeface.

[0042] 8 and 9 are figures corresponding to FIGS. 6 and 7 when the population is male. That is, FIG. 8 is a figure for explaining the selection of gut microbial variables when the population is male according to this embodiment. FIG. 9 is a table showing the effect size value, application to the association model described below, and factors related to MCI for each gut bacteria in FIG. 8. In the case of FIG. 9, since the population is male, the item "Gut bacteria common in MCI (in women)" is not marked. In addition, the item "Protection of IgA from trypsin digestion" is not marked because the corresponding gut bacteria does not appear in FIG. 9.

[0043] It is confirmed whether or not all of the multiple intestinal bacteria estimated in S110 correspond to the MCI-related factors described in Fig. 7. In this embodiment, by performing such confirmation, it becomes possible to perform the point-addition process described later.

[0044] First, the MCI-related factors in FIG. 7 will be described with reference to FIG. 10. FIG. 10 is a hypothetical conceptual diagram of the influence of intestinal flora associated with MCI according to this embodiment. In the figure, an upward bold arrow indicates an increase, and a downward bold arrow indicates a decrease. For example, an upward bold arrow is added to "decomposition of IgA." In this case, it means "the decomposition of IgA is promoted."

[0045] In this embodiment, a comparative study was conducted in advance to formulate the hypothesis shown in FIG. 10. Specifically, the association between MCI and gut microbiota was investigated by comparing an MCI group (11 men, 18 women) in their 70s with a control group (17 men, 23 women) taking gender into consideration. A literature search was also conducted on the known characteristics, such as hydrogen production, of the multiple gut bacteria associated with MCI revealed by this comparative study. Some of the multiple gut bacteria were not described in the literature as being associated with MCI. However, based on some of the known characteristics and this comparative study, it was hypothesized that the composition of the gut microbiota in the MCI group causes dysregulation of the gut microbiota, increased intestinal barrier permeability, increased blood-brain barrier permeability, and enhanced chronic neuroinflammation, and that the abnormalities persist for a long period of time, ultimately leading to cognitive decline.

[0046] In addition, the comparative study was conducted by gender, and if the absolute value of the effect size was 0.2 or more, it was set as being related to the MCI group. Some of the gut bacteria in Figure 10 have "(male) or (female)" written next to the name of the gut bacteria. This means "(MCI-related factors that are common in men) or (MCI-related factors that are common in women)."

[0047] In this embodiment, in addition to the analysis of the mixed gender group, reanalysis was performed for groups separated by gender to try to understand the relationship between MCI and intestinal flora. As a result, it became possible to explain, although it is a hypothesis, a part of the mechanism of MCI related to intestinal bacteria as shown in FIG. 10. By formulating such a hypothesis, this embodiment makes it possible to set MCI-related factors and construct a model that calculates the probability that a subject has or will have MCI. Then, in this embodiment, as described later, an association model and a score estimation model related to MCI are created, and further, a risk calculation model is created. This risk calculation model corresponds to a model that calculates the probability that a subject has or will have MCI.

[0048] Figure 10 is a conceptual diagram of a hypothesis regarding part of the mechanism of MCI involving gut bacteria. Below, we explain the hypothesis regarding the influence of gut microbiota related to MCI by item. (1) A decrease in the hydrogen-producing bacteria Roseburia, Megasphaera, Victivallis, Ruminococcus (male), and Agathobacter (female), and an increase in Eggerthella, which oxidizes bile acids depending on the hydrogen concentration, lead to dysregulation of the gut microbiota. (2) A decrease in the hydrogen-producing bacteria Roseburia, Megasphaera, Victivallis, Ruminococcus (male), and Agathobacter (female) indirectly causes an increase in intestinal pH due to a decrease in the production of acetic acid, leading to dysregulation of the gut microbiota. (3) An increase in Erysipelatoclostridium, which produces IgA protease, and a decrease in Paraprevotella (female), which protects IgA through the decomposition of intestinal trypsin, lead to dysregulation of the gut microbiota and increased inflammation in intestinal epithelial cells. (4) An increase in Clostridium_XVIII and Ruminococcus 2, which are related to the decomposition of the mucin layer, and a decrease in Roseburia (flagellin), which is related to the protection of the intestinal barrier function, lead to increased intestinal barrier permeability. (5) An increase in Erysipelatoclostridium, which promotes intestinal serotonin secretion, leads to increased blood-brain barrier permeability. (6) The intestinal bacteria that increase due to dysregulation of the intestinal flora differ between men and women, but they are factors that contribute to inflammation. (7) A decrease in bacteria that produce HDAC (histone deacetylase) inhibitors (valeric acid-producing bacteria: Oscillibacter and Megasphaera, propionic acid and butyric acid-producing bacteria: Roseburia, etc.) causes epigenetic dysregulation by excessive HDAC, leading to increased inflammation. (8) A decrease in the hydrogen-producing bacteria Roseburia, Megasphaera, Victivallis, Ruminococcus, and Agathobacter leads to decreased scavenging of hydrogen-producing reactive oxygen species, leading to increased chronic inflammation.(9) The composition of the gut microbiota in MCI patients leads to dysregulation of the gut microbiota, increased intestinal barrier permeability, increased blood-brain barrier permeability, and enhanced chronic neuroinflammation, and these abnormalities persist for a long period of time, ultimately leading to a decline in cognitive function.

[0049] In Figure 10, the "gut bacteria group common to MCI" and "gut bacteria group rare to MCI" found in the above-mentioned comparative study are further classified into three subgroups: male, female, and common to both sexes. This classification is shown as an enlarged diagram in Figure 11 due to space limitations. In addition, the underlined "item names" and "gut bacteria names" in Figures 10 and 11 are not applicable in the above-mentioned literature survey. For example, it is known that hydrogen is involved in MCI. However, although the intestinal bacteria Megasphaera, Victivallis, and Agatho- bacter (female) are known to have hydrogen production ability, it was found for the first time in this survey that these intestinal bacteria are related to MCI. Therefore, these intestinal bacteria are underlined.

[0050] In this embodiment, MCI-related factors can be set based on a hypothesis of the mechanism of MCI in which intestinal bacteria are involved. More specifically, the items in which the names of intestinal bacteria shown in Figures 10 and 11 are written can be set as MCI-related factors.

[0051] (Point addition process 1: Point addition using attribute information) FIG. 12 shows the relationship between age and occupancy rate of all female subjects for Bifidobacterium, one of the intestinal bacteria with a negative effect size in women in FIG. 6. In FIG. 12, Healthy is the average value for each age in the control group, and MCI is the average value for each age in the MCI group. At younger ages, there are no MCI sufferers. Therefore, for ages where data on MCI sufferers cannot be measured, an estimated value is used as the occupancy rate for that age (shown as MCI (estimated value) in FIG. 12). The occupancy rate refers to the proportion of a certain intestinal bacteria in the intestinal flora.

[0052] Accumulation of brain damage is involved in the onset of MCI. In addition, the intestinal flora changes with age. As described later, in this embodiment, a score addition process may be performed using attribute information such as the subject's age.

[0053] As can be seen from FIG. 12, the judgment of whether the occupancy rate of Bifidobacterium is appropriate or not differs depending on the age of the female subject. For example, assume that the age of the subject is 60 years old. The average values ​​for a 60-year-old in FIG. 12 are Healthy at 6.9% and MCI at 3.2%. Therefore, if the occupancy rate of Bifidobacterium in the subject's intestinal flora is 6.9% or more, no additional points are added. On the other hand, if the occupancy rate of the subject is 3.2% or less, additional points are added to Bifidobacterium.

[0054] (Additional points treatment 2: Additional points for intestinal bacteria that correspond to factors related to MCI) In this embodiment, when the subject possesses all of the MCI-related factors among the multiple intestinal bacteria estimated in S110, the intestinal bacteria corresponding to the MCI-related factors among the multiple intestinal bacteria estimated in S110 may be added. FIG. 13 is a diagram for explaining the addition of points according to the bacteria possessed according to this embodiment. This diagram shows a case where the subject in the MCI group is a woman. For this reason, "intestinal bacteria that are common in MCI (in the case of men)" and the like are excluded from the MCI-related factors. It shows that for subjects in the MCI group who have been given scores (a numerical value different from 0, which is an occupancy rate or the number of sequences) for all MCI-related factors (i.e., when the intestinal microflora of the subject possesses all of the MCI-related factors), a process of adding points is performed for the corresponding bacteria possessed. Note that in this embodiment, when all of the MCI-related factors are possessed, points are added because it is considered that the involvement in MCI is accelerated, but points may be added if some of the MCI-related factors are possessed.

[0055] Returning to the process of S110, the step of creating an association model using the intestinal bacteria estimated in S115 will be described. In this embodiment, the association model is created using the CLR-converted intestinal microbiota data of the NC and MCI groups and the MCI morbidity status data.

[0056] FIG. 14 is a diagram showing the results of estimating parameters of the association model according to this embodiment. The population is female. Here, a structural equation model (SEM) is used as one of the association models. A structural equation model represents the relationship between observed variables and latent variables, and the relationship between the latent variables. Therefore, an association model is a statistical analysis model constructed by observed variables that are correlated with a specific disease to a certain degree or higher, and latent variables that are related to the observed variables.

[0057] Association model 1 is the area surrounded by a solid line. Rectangles represent observed variables, "e" represents the residual variance of the observed variables, ellipses represent latent variables, and the numbers on the arrows from latent variables to observed variables or other latent variables represent the standardized parameters of the association model. For example, the observed variable MCI is an observed variable related to the disease MCI, and is defined as a binary categorical variable representing the MCI morbidity status. If the individual has MCI, it is "1", and if the individual does not have MCI, it is "0".

[0058] In constructing the association model, we assumed that there were two latent variables that explained the MCI status variable: Lv1 had a positive effect on MCI, and Lv2 had a negative effect.

[0059] First, all the gut bacteria shown in Figure 6 are assigned as observed variables (also called gut microbe variables) of latent variables Level 1 or Level 2. This is the initial association model. Starting from this initial association model, the model is modified. In modifying the model, observed variables are deleted until no negative components appear in each variance-covariance matrix calculated in the structural equation modeling process.

[0060] After that, observed variables are deleted so that the p-value (significance probability) of each parameter is less than 0.05, and from the constructed models, the one with GFI (Goodness of Fit Index) and AGFI (Adjusted GFI) values ​​close to 1, RMSEA (Root Mean Square Error of Approximation) value close to 0, and the absolute value of the path coefficient from the latent variable to the disease incidence status variable is the largest is adopted as the final association model.

[0061] The created association model is fed with data on the combined population of NC and MCI groups (i.e., gut microbiota data and MCI incidence data), and each parameter in the association model is calculated. By doing so, when focusing on the NC and MCI groups, we investigate how the gut bacteria, set as an observed variable, explains the variables representing the MCI incidence status through the hypothesized latent variables (Lv1, Lv2).

[0062] The standardized path coefficient from the latent variable Lv1, which is assumed to have a positive effect on MCI, to the MCI prevalence variable is 0.52 (p<0.01), and the standardized path coefficient from the latent variable Lv2, which is assumed to have a negative effect on MCI, to the MCI prevalence variable is -0.52 (p<0.01). The standardized factor loading from the latent variable Lv1 to each observed variable (gut microbe variable) of Lv1, for example, Ruthenibacterium, is 0.65. The standardized factor loading from the latent variable Lv2 to each observed variable (gut microbe variable) of Lv2, for example, Megamonas, is 0.85. All standardized factor loadings from the latent variables to each observed variable (gut microbe variable) are significant at p<0.05. The value of the arrow between the latent variables, -0.41, represents the magnitude of correlation between Lv1 and Lv2.

[0063] The residual variance of the MCI status variable was 0.24, and in this association model, the two hypothesized latent variables (Lv1, Lv2) explained approximately 76% of the variance of the MCI status variable.

[0064] In this embodiment, S115 is an example of a method for selecting observed variables of the association model, and the gut microbial variables are estimated using the effect amount as an index. S115 is not an essential configuration.

[0065] The relationship between the observed variables related to the latent variables (Lv1, Lv2) in FIG. 14 and the intestinal bacteria marked with a check mark in the "association model" column in FIG. 7 will be described. The observed variables related to the latent variable Lv1 in FIG. 14 are given numerical values ​​in the effect amount "MCI" column in FIG. 7, and are marked with a check mark in the "association model" column. Similarly, the observed variables related to the latent variable lv2 are given numerical values ​​in the effect amount "Healthy" column, and are marked with a check mark in the "association model" column. In this way, it can be seen that the intestinal bacteria marked with a check mark in the "association model" column in FIG. 7 are applied to the association model of this embodiment.

[0066] There are various ways to select observed variables for the association model. For example, some statistical test (such as Wilcoxon rank sum test) can be performed between the control group and the MCI group, and the intestinal bacteria that are significantly different in abundance between the two groups can be used as observed variables for the association model. Alternatively, intestinal bacteria that have already been reported as having the potential to be biomarkers for the target disease can be used as observed variables for the association model.

[0067] (Explanation of S120) S120 is a step of creating a model that estimates the score of the latent variable when the MCI prevalence status is unknown. When creating the association model, data of the combined population of NC and MCI groups (i.e., gut microbiota data and MCI prevalence status data) is used. However, the subjects are those who wish to be evaluated for risk of MCI, and their disease prevalence status is unknown. Therefore, a model that estimates the score of the latent variable when the MCI prevalence status is unknown is required.

[0068] In order to estimate the scores of Level 1 and Level 2 when the MCI status of a female subject is unknown, a portion of the measurement equation model (dotted line in FIG. 14) is extracted from the association model 1 to create a score estimation model 2. For this purpose, the same value as that of each parameter of the measurement equation model is set to the value of each parameter of the score estimation model 2. Here, the measurement equation model is a model showing the influence of the latent variable on the observed variable of intestinal bacteria (intestinal microorganism variable). The score estimation model 2 of this embodiment is a linear multiple regression model with the observed variable of intestinal bacteria (intestinal microorganism variable) as the explanatory variable and the scores of the latent variables (Lv1 and Lv2) as the objective variable.

[0069] In this embodiment, the subject's attribute information and / or intestinal bacteria information corresponding to factors related to MCI is used to add points to the score estimation model 2, and then the subject's scores at Level 1 and Level 2 are estimated. Hereinafter, the estimated values ​​of the latent variables Lv1 and Lv2 are represented as Lv1est and Lv2est, respectively.

[0070] (S200 explanation) S200 is a step in which the subject inputs the disease for which the subject wishes to be evaluated. In this embodiment, the score estimation model for MCI is created separately for each gender. Therefore, the subject also inputs his / her gender. The subject is female.

[0071] (Explanation of S210) S210 is a step of extracting the subject's gut microbiota data and attribute information. The subject submits a stool sample, and the subject's gut microbiota data is stored in the gut microbiota DB300. S210 extracts the subject's gut microbiota data from the gut microbiota DB300 using the subject's ID information. Furthermore, the subject's attribute information (age, area where the subject lived during childhood, etc.) is extracted from the questionnaire response data submitted by the subject.

[0072] (Explanation of S220) S220 is a step of adding points to the score estimation model using attribute information of the subject and / or information of intestinal bacteria corresponding to factors related to MCI. Attribute information of the subject is input to the disease evaluation index calculation device 900.

[0073] The point adding unit 910 obtains a composite variable x (x1=attribute, x2=living area, ...) from the subject's attribute information. Next, the composite variable x is input to a predetermined point adding function y=f(x), and the value y output by the point adding function is added to the variable (e.g., Erysipelatoclostridium in FIG. 14) that is related to Level 1 and has a check mark in the "MCI-related factor" column in FIG. 7, among the intestinal microbial variables.

[0074] Fig. 15 is a diagram for explaining a score estimation model after the addition of points and a risk calculation model according to this embodiment. Each gut microbe variable with an apostrophe (for example, Erysipelatoclostridium') in Fig. 15 is a gut microbe variable (observed variable) after the addition of points. For example, Erysipelatoclostridium' = Erysipelatoclostridium + y.

[0075] Among the variables related to Lv1, Flavonifractor is not marked in the "MCI-related Factor" column in Fig. 7, so no points are added and no apostrophe is added. In this embodiment, points are added to some of the variables related to Lv1, but depending on the settings of the MCI-related factors, points may be added to all variables related to Lv1. In addition, the MCI-related factors may be set so that points are added to variables related to all latent variables (Lv1 and Lv2).

[0076] The portion surrounded by a dotted line in FIG. 15 is a score estimation model 2' after adding points. Also, the portion surrounded by a dashed line in FIG. 15 is a risk calculation model 3' described below. Note that in the whole portion 1' in FIG. 15, the variable values ​​of the intestinal microorganism variables in the association model in FIG. 14 have been changed. For example, the variable value of the intestinal microorganism variable Erysipelatoclostridium has been changed to "Erysipelatoclostridium+y".

[0077] (Explanation of S230) S230 is a step of estimating the score of the latent variable using the score estimation model 2' after the addition of points for MCI. Specifically, second data on factors or intestinal microorganisms that are suggested to be related to MCI are extracted from the first data on the intestinal microflora of the subject. The second data on factors or intestinal microorganisms that are suggested to be related to MCI are input to each observed variable (e.g., Erysipelatoclostridium') of the score estimation model 2', and the scores of the subject for the latent variables Lv1 and Lv2 of the score estimation model 2' are estimated. The estimated values ​​of the latent variables Lv1 and Lv2 are set as Lv1est and Lv2est. That is, S230 inputs the second data into a model (score estimation model 2') that uses the added intestinal microorganisms as variables and calculates the probability that the subject has a disease, and estimates the scores of the subject for the latent variables Lv1 and Lv2 of the score estimation model 2'. Here, the added intestinal microorganisms may be called the second data after the addition of points. The first data corresponds to data on the gut microbiota of the subject. The second data corresponds to the gut microbiota of the subject, for example, with a check in the "association model" column in FIG. 7. The third data corresponds to the gut microbiota of the subject, with a check in the "association model" column. That is, the third data corresponds to one or more gut microbiota that show differences between the gut microbiota of a healthy person and the gut microbiota of a person suffering from mild cognitive impairment.

[0078] (Explanation of S240) S240 is a step of calculating an evaluation index of risk for MCI. Specifically, the risk of MCI of the subject is calculated using the path coefficients from the latent variables Lv1 and Lv2 to the observed variable MCI in the risk calculation model 3' in Fig. 15 and the estimated values ​​(Lv1est, Lv2est) of the latent variables Lv1 and Lv2. That is, S240 calculates the risk of MCI of the subject in the risk calculation model 3' based on the probability calculated by the score estimation model 2' (the subject's scores of the latent variables Lv1 and Lv2 of the score estimation model 2').

[0079] In this embodiment, a logistic regression model is used to construct the MCI incidence probability estimation model, in which the latent variables Lv1 and Lv2 are explanatory variables and a binary categorical variable representing the subject's MCI incidence status is the objective variable. This logistic regression model corresponds to the risk calculation model 3' (dashed line in FIG. 15).

[0080] The disease evaluation index calculation device 900 outputs an evaluation report to the subject based on the calculated risk of MCI.

[0081] The above is the flow chart of the disease evaluation index calculation process in Fig. 2. In the case where the population is female, in the association model 1 for MCI, the correlation between the factors of the latent variables Lv1 and Lv2 in Fig. 14 is -0.41. On the other hand, in the case where the population is male, it is assumed that there is a correlation between Lv1 and Lv2, and there is one latent variable. Below, the case where there is one latent variable will be described as a modified example.

[0082] (Modification; one latent variable) FIG. 16 is a diagram showing the results of estimating parameters of the association model 1 according to the modified example. The population is male. FIG. 17 is a diagram for explaining a score estimation model 2' after adding points and a risk calculation model 3' according to the modified example. The modified example shows a case where there is one latent variable. All of the variables related to Level 1 in FIG. 17 have a check mark in any of the items in the "MCI-related factors" column in FIG. 9, so all of them have been added points and an apostrophe has been added.

[0083] Even when there is one latent variable, S110 (creating an association model), S120 (creating a score estimation model), S220 (adding points using the subject's attributes), S230 (estimating the score of the latent variable), and S240 (calculating the risk) in Figure 2 can be processed as described above.

[0084] (Example of risk calculation) The calculation of the risk of MCI will be described separately for this embodiment (the population is female) and the modified example (the population is male). Figure 18 is a diagram showing the results of ROC analysis on the risk value of MCI according to this embodiment (the population is female). The calculation of the risk according to this embodiment (the population is female) and the accuracy of the calculated risk will be described.

[0085] For the female subject group, the combined NC and MCI group is randomly divided into an 80% training group and a 20% validation group. An association model is trained using the latent variable scores (Lv1 and Lv2) of the training group and information on MCI incidence status, and an MCI incidence probability estimation model is constructed to estimate the MCI incidence probability from the latent variable scores. The latent variable score estimates (Lv1est and Lv2est) of the validation group are applied to the constructed MCI incidence probability estimation model, and the accuracy of the MCI incidence probability estimation model is examined by ROC (Receiver Operating Characteristic) analysis. The MCI incidence probability is the risk of developing MCI, and the results of the ROC analysis can be used as a disease evaluation index.

[0086] The method for constructing the MCI incidence probability estimation model uses a logistic regression model in which the latent variables Lv1 and Lv2 are the explanatory variables and the binary categorical variable representing the subject's MCI incidence status is the objective variable. This logistic regression model corresponds to risk calculation model 3' in Figure 15.

[0087] FIG. 18 shows the ROC curve for this logistic regression model. The vertical axis represents "Sensitivity". When the probability of determining that a person who actually has MCI has MCI increases, the value of the vertical axis approaches 1. The horizontal axis represents "1-Specificity". When the probability of determining that a person who does not have MCI does not have MCI increases, the value of specificity approaches 1. Since the horizontal axis subtracts specificity from 1, when the value of the horizontal axis approaches 0, the probability of determining that a person who does not have MCI does not have MCI increases. The solid line shows the results of a model (this embodiment (population is female) described in FIGS. 14 and 15) with Lv1 and Lv2 as explanatory variables. The AUC represents the value of the Area Under the Curve, which is 0.87 in this embodiment (population is female).

[0088] In Fig. 18, the diagonal line (dotted line) represents a probability of 0.5, and in the case of a model (solid line) with Lv1 and Lv2 as explanatory variables, the area enclosed by the solid and dotted lines is wide, and it can be visually (or intuitively) determined that the accuracy of the risk estimation method is high. Furthermore, AUC is an index of a risk estimation method, and it can be objectively determined that a good risk estimation method is one with an AUC value close to 1. This embodiment can be determined to have high accuracy as an indirect risk estimation method, excluding direct risk estimation methods such as blood tests.

[0089] 19 is a diagram showing the results of an ROC analysis of the risk value of MCI for the modified example (population is male). The AUC is 0.75. Therefore, like the present embodiment (population is female), the modified example can be judged to have high accuracy as an indirect risk estimation method, excluding direct risk estimation methods such as blood tests.

[0090] (effect) According to this embodiment, an association model for each disease (e.g., association model 1 in FIG. 14) is created using gut microbiota data and disease morbidity data of a large number of subjects, and a score estimation model (e.g., score estimation model 2 in FIG. 14) is created in advance from the measurement equation part of the association model. For subjects who wish to be evaluated for risk of MCI as a specific disease, individual processing can be performed according to the stool sample and questionnaire response data submitted by the subjects in the same way as for a large number of subjects.

[0091] The subject's gut microbiota data is extracted using a stool sample submitted by the subject. In addition, the subject's attribute information (including the subject's background at birth and childhood background) is extracted using the questionnaire response data submitted by the subject. The subject's attribute information is used to add points to a score estimation model for MCI (e.g., score estimation model 2 in FIG. 14). The subject's score for the latent variable can be estimated by inputting the subject's gut microbiota data into the observed variable of the score estimation model after the addition (e.g., score estimation model 2' after the addition in FIG. 15). The subject's estimated score and a risk calculation model (e.g., risk calculation model 3' in FIG. 15) can be used to calculate the subject's risk of MCI.

[0092] The subject can easily receive the assessment report on his / her own risk of suffering from MCI in a non-invasive manner. Also, the business providing the assessment report can design, consider, and propose prebiotics to the subject.

[0093] For example, by including in the subject's assessment report the subject's risk of MCI as well as prescriptions for functional foods or other medications based on the subject's gut microbiome data, assessment companies can provide subjects with solutions for improving cognitive function.

[0094] (Solution for improving cognitive function) In addition to the risk of MCI, the evaluation report for the subject may also introduce functional foods that are expected to improve the cognitive function of the subject. In this embodiment, the cognitive function improving foods are introduced according to the gut microbiota data of the subject.

[0095] In this embodiment, from among these foods for improving cognitive function, functional foods (foods for improving cognitive function) that increase the intestinal microflora that contributes to improving MCI are identified according to the gut microflora data of the subject, and a report on how to take the identified functional foods is provided (or prescribed) to the subject. The subject regularly takes the identified functional foods according to the intake method. Then, the cognitive function improvement solution can be used by using the cognitive function index calculation system of this embodiment again as a follow-up several months later. The cognitive function improvement solution can provide the subject with an evaluation report before and after taking the functional foods.

[0096] For example, the observed variable MCI in the association model 1 in Fig. 14 is an observed variable related to the disease MCI, and is defined as a two-value categorical variable representing the MCI morbidity status, but is not limited to this. The observed variable MCI may be set to a continuous value of 0 to 100, and an intervention test may be performed to confirm the increase or decrease of MCI when a subject takes a functional food that affects gut microbial variables that may be a cause of MCI (risk factor or preventive factor).

[0097] Although the embodiments (including modified examples) of the present invention have been described above, two or more of these embodiments may be combined and implemented. Alternatively, one of these embodiments may be partially implemented. Furthermore, two or more of these embodiments may be partially combined and implemented.

[0098] Furthermore, the present invention is not limited to the above-mentioned embodiment. Various modifications within the scope of the claims and within the scope of those skilled in the art are also included in the present invention.

[0099] For example, although it is assumed that there are one or two latent variables, there may be three or more. In addition, in this embodiment, ID information of subjects related to a disease is extracted for each attribute of male and female from the questionnaire DB 400, and an association model is created, but this is not limited to this. A mixed model of male and female may be created without extracting each attribute of male and female.

[0100] In addition, in S230, when estimating the score of the latent variable, the score estimation model after the point addition is used, but this is not limited to this. A score estimation model before the point addition may be used without performing the point addition process.

[0101] Intestinal microorganisms that have been suggested to be associated with MCI may also be: Acidaminococcus, Adlercreutzia, Agathobacter, Akkermansia, Anaeromassilibacillus, Anaerostipes, Anaerotignum, Anaerotruncus, Bacteroides, Bifidobacterium, Blautia, Catenibacterium, Clostridium IV, Clostridium sensu stricto, Clostridium XlVa, Clostridium XlVb, Clostridium XVIII, Coprobacillius, Coprobacter, Coprococcus, Dialister, Dysosmobacter, Eggerthella, Eisenbergiella, Enterocloster, Enterococcus, Erysipelatoclostridium, Faecalicatena, Flovonifractor, Fournierella, Frisingicoccus, Fusobacterium, Gordonibacter, Holdemanella, Holdemania, Hungatella, Ihubacter, Intestinibacter, Intestinimonas, Lactococcus, Lawsonibacter, Leuconostoc, Ligilactobacillus, Longicatena, Massilimicrobiota, Megamonas, Megasphaera, Merdimonas, Negativibacillus, Neglecta, Oscillibacter, Parabacteroides, Paraprevotella, Parasutterella, Prevotella, Romboutsia, Roseburia, Rothia, Ruminococcus, Ruminococcus2, Ruthenibacterium, Sellimonas, Slackia, Streptococcus, Sutterella, Turicibacter, Unclassified (DNA sequences without assigned taxonomic names), Veillonella, Victivallis.

[0102] In this embodiment, an association model is used, but the present invention is not limited to this, and may be performed by machine learning. When using an association model, the disease evaluation index calculation device according to this embodiment includes an input unit for inputting one or more diseases that a subject wishes to be examined, a first database for storing data on the intestinal microbiota that is the result of analyzing stool samples from multiple subjects, a second database for storing questionnaire response data on the disease from the subject, an extraction unit for extracting first intestinal microbiota data of a healthy person and second intestinal microbiota data of a person suffering from the disease using a predetermined extraction condition, and an input unit for inputting the first intestinal microbiota data, the second intestinal microbiota data, and the questionnaire response data, and extracting a first observation variable related to multiple intestinal microorganisms that indicates a difference between the first intestinal microbiota data and the second intestinal microbiota data, a second observation variable that indicates the disease condition, and one or more observation variables related to the first observation variable and the second observation variable. and a first creating unit that creates an association model composed of a latent variable of the first observation variable and a parameter between the first and second observation variables and / or a parameter between the multiple latent variables from the one or more latent variables, a second creating unit that creates a score estimation model with the first observation variable as an explanatory variable and the score of the latent variable as a target variable, a score adding unit that inputs attribute information of a subject who wishes to be evaluated for the disease and adds a part of the explanatory variables of the score estimation model using the attribute information of the subject, an estimation unit that inputs gut microbiota data of the subject to the explanatory variables of the score estimation model to which the score has been added and estimates the score of the latent variable, and a calculation unit that calculates the risk of the subject against the disease using the parameters from the one or more latent variables to the second observation variable and / or the parameters between the multiple latent variables and the estimated score. Of these configurations, the first creating unit, the second creating unit, the score adding unit, the estimation unit, and the calculation unit may be performed by machine learning. [Explanation of symbols]

[0103] 100 Intestinal microbial DNA extraction device 200 Intestinal microbiome analysis device 300 Intestinal microbiome DB 400 Survey DB 500 Association model creation device 600 Association Model DB 700 Score Estimation Model Creation Device 800 score estimation model DB 900 Disease evaluation index calculation device 910 Addition section

Claims

1. An extraction unit that extracts a factor or second data on gut microbes suggested to be associated with mild cognitive impairment from first data on the gut microbiome of the subject; A calculation unit that inputs the second data into a model that calculates the probability that the subject has the mild cognitive impairment using third data related to one or more gut microorganisms that show a difference between the gut microbiota of a healthy person and the gut microbiota of a person suffering from the mild cognitive impairment as a variable, and calculates the risk of the subject for the mild cognitive impairment; A mild cognitive impairment risk index calculation device comprising:

2. The mild cognitive impairment risk index calculation device of claim 1, wherein the second data is classified into an intestinal microbial group that is prevalent in the mild cognitive impairment and an intestinal microbial group that is rare in the mild cognitive impairment.

3. The mild cognitive impairment risk index calculation device according to claim 2, wherein the intestinal microbial group that is prevalent in mild cognitive impairment and the intestinal microbial group that is low in mild cognitive impairment are each classified into three subgroups: male, female, and unisex.

4. The mild cognitive impairment risk index calculation device of claim 1, wherein the second data relates to mucin degradation, IgA protease production, serotonin secretion from enterochromaffin cells, oxidation of bile acids, promotion of recovery of intestinal barrier function, production of HDAC inhibitors, or protection of IgA from trypsin degradation.

5. The extraction unit also extracts attribute information of the subject, The calculation unit scores the second data using attribute information of the subject and / or information on intestinal microorganisms corresponding to factors related to the mild cognitive impairment, and inputs the second data after the scoring into the model. The mild cognitive impairment risk index calculation device of claim 1.

6. The mild cognitive impairment risk index calculation device according to claim 4 , wherein the subject's attribute information includes background information of the subject at the time of birth and background information of the subject's life in childhood.

7. The mild cognitive impairment risk index calculation device according to claim 1 , wherein the model is a model created for each attribute of male and female, or a mixed male and female model.

8. The computer Extracting second data on factors or gut microbes suggested to be associated with mild cognitive impairment from the first data on the gut microbiota of the subject; A method for calculating a risk index of mild cognitive impairment, comprising: inputting the second data into a model that calculates the probability that the subject has mild cognitive impairment using third data regarding one or more intestinal microorganisms that indicate a difference between the intestinal microbiota of a healthy person and the intestinal microbiota of a person suffering from mild cognitive impairment as a variable; and calculating the subject's risk of mild cognitive impairment.

9. A step of extracting a factor or second data on gut microbes suggested to be associated with mild cognitive impairment from the first data on the gut microbiome of the subject; A calculation step of inputting the second data into a model that calculates the probability that the subject has the mild cognitive impairment using third data regarding one or more gut microorganisms that indicate a difference between the gut microbiota of a healthy person and the gut microbiota of a person suffering from the mild cognitive impairment as a variable, and calculating the risk of the subject for the mild cognitive impairment; A program for calculating a risk index for mild cognitive impairment that is executed on a computer.

Citation Information

Patent Citations

  • Gut microbiota-related methods for treating dementia and age-dependent cognitive decline

    JP2023508968A

  • Disease evaluation index calculation system, method, and program

    JP7270143B1

  • Composition for preventing or treating deterioration in brain function or maintaining or improving brain function

    WO2022118944A1

  • Food composition for cognitive function improvement, cognitive function improver, and method for producing the same

    JP2019180364A